摘要
新型冠状病毒肺炎(COVID-19)被发现以来,迅速蔓延,其早期诊断有利于患者的及时救治和疾病进一步传播的有效控制。目前,诊断的依据是流行病史、临床表现、影像学特征和逆转录聚合酶链式反应(RT-PCR)检测结果,其中RT-PCR检测到新型冠状病毒核酸阳性是COVID-19确诊的主要依据,影像学特征尤其是肺部高分辨率CT表现则是诊断该病的重要临床依据。作为一种被广泛应用的影像学方法,^(18)F-FDG PET/CT在COVID-19中的价值仍未可知。笔者分析了^(18)F-FDG PET/CT在COVID-19中的诊断和鉴别诊断的价值,以及评估COVID-19患者纵隔淋巴结受累情况方面的潜在应用,讨论了COVID-19患者肺外器官和组织受累可能出现的^(18)F-FDG PET/CT影像学表现。
COVID-19 has been rapidly spreading since its discovery.Early diagnosis benefits the patients and helps control the spread of COVID-19.At present,the diagnosis of COVID-19 is based on epidemiology,clinical characteristics,imaging features,and reverse transcription-polymerase chain reaction(RT-PCR)test.The diagnosis of COVID-19 is confirmed by RT-PCR test,which detects a positive severe acute respiratory syndrome coronavirus 2 nucleic acid.Imaging features,especially lung high-resolution CT features,are essential for the clinical diagnosis of COVID-19.^(18)F-FDG PET/CT is a widely used imaging modality,but its value for COVID-19 diagnosis is still unknown.This review summarizes the potential value of ^(18)F-FDG PET/CT for the diagnosis,differential diagnosis,and assessment of mediastinal lymph node involvement.The possible imaging features of extrapulmonary involvement in patients with COVID-19 are also discussed.
作者
朱子扬
兰晓莉
安锐
Ziyang Zhu;Xiaoli Lan;Rui An(Key Laboratory of Molecular Imaging of Hubei Province,Nuclear Medicine Quality Control Center of Hubei Province,Department of Nuclear Medicine,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China)
出处
《国际放射医学核医学杂志》
2020年第10期616-621,共6页
International Journal of Radiation Medicine and Nuclear Medicine
